490. Comparison of Clostridium difficile Infection Outcomes by Diagnostic Testing Method
Session: Poster Abstract Session: Healthcare Epidemiology: Updates in C. difficile
Thursday, October 4, 2018
Room: S Poster Hall
Background: U.S. laboratories are increasingly using nucleic acid amplification tests (NAAT) to diagnose Clostridium difficile infection (CDI) due to their increased sensitivity over toxin enzyme immunoassays (EIA), but NAATs may be more likely than toxin EIAs to detect colonization rather than true disease. Limited data indicate patients positive by toxin EIA (toxin+) have worse outcomes than those positive by NAAT (NAAT+) only, suggesting toxin EIA detects true infection more often than NAAT. We used multisite CDI surveillance data from the Centers for Disease Control and Prevention’s Emerging Infections Program to compare clinical course and outcomes between toxin+ and NAAT+ only patients.

Methods: A case was defined as a positive C. difficile test in a person ≥1 year old with no positive tests in the prior 8 weeks. Cases detected during 2014–15 by a testing algorithm using toxin EIA and NAAT were classified as toxin+ or NAAT+ only. Medical charts were reviewed. Death data were obtained from state death registries. Multivariable logistic regression models were used to compare CDI recurrence and 90-day mortality between the two groups, adjusting for age, sex, race, Charlson comorbidity index, and receipt of oral vancomycin. For the outcome of recurrence, we also adjusted for history of CDI in the prior 6 months.

Results:

Of 4878 cases, 2160 (44%) were toxin+ and 2718 (56%) were NAAT+ only. Toxin+ cases were more likely than NAAT+ only cases to be ≥65 years old (48% vs 38%; P<.0001), have white blood cells ≥15,000/µl (483/1539 [31%] vs 423/1978 [21%]; P<.0001), and have received oral vancomycin ≤3 days of diagnosis (32% vs 29%; P=.03). Comparing toxin+ to NAAT+ only cases, 21% vs 11% had a recurrence (P<.0001), of which 71% vs 33% had a toxin+ recurrence (P<.0001), and 10% vs 9% died ≤90 days of diagnosis (P=.12). In multivariable analysis, a toxin+ result was associated with recurrence (adjusted odds ratio [aOR]: 1.89, 95% CI: 1.61-2.22) but not with 90-day mortality (aOR: 0.99; 95% CI: 0.81-1.22).

Conclusion: Toxin+ CDI is more severe by some markers and more likely to recur as toxin+­. However, there was no difference in adjusted mortality, which may reflect an effect on mortality in NAAT+ only cases from mild CDI, receipt of unnecessary CDI treatment, or other factors.

Alice Guh, MD, MPH1, Kelly Hatfield, MSPH1, Lisa G. Winston, MD2, Brittany Martin, MPH3, Helen Johnston, MPH4, Geoff Brousseau, MPH4, Monica M. Farley, MD, FIDSA5,6, Lucy E. Wilson, MD, ScM7, Rebecca Perlmutter, MPH7, Erin C. Phipps, DVM, MPH8, Ghinwa Dumyati, MD, FSHEA9, Deborah Nelson, MSN, RN9, Trupti Hatwar, MPH9, Marion A. Kainer, MBBS, MPH10 and L. Clifford McDonald, MD1, (1)Centers for Disease Control and Prevention, Atlanta, GA, (2)Medicine, University of California, San Francisco and Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, CA, (3)California Emerging Infections Program, Oakland, CA, (4)Colorado Department of Public Health and Environment, Denver, CO, (5)Department of Medicine, Emory University School of Medicine and Atlanta VA Medical Center, Atlanta, GA, (6)Georgia Emerging Infections Program, Atlanta, GA, (7)Maryland Department of Health, Baltimore, MD, (8)New Mexico Emerging Infections Program, University of New Mexico, Albuquerque, NM, (9)NY Emerging Infections Program, Center for Community Health and Prevention, University of Rochester Medical Center, Rochester, NY, (10)Communicable and Environmental Diseases and Emergency Preparedness, Tennessee Department of Public Health, Nashville, TN

Disclosures:

A. Guh, None

K. Hatfield, None

L. G. Winston, None

B. Martin, None

H. Johnston, None

G. Brousseau, None

M. M. Farley, None

L. E. Wilson, None

R. Perlmutter, None

E. C. Phipps, None

G. Dumyati, Seres: Scientific Advisor , Consulting fee .

D. Nelson, None

T. Hatwar, None

M. A. Kainer, None

L. C. McDonald, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.